BCA
ITCI

Berman Capital Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Berman Capital Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
36
+30
+500% +$1.04K ﹤0.01% 2001
2021
Q2 		$0 Hold
6
– – ﹤0.01% 2078
2021
Q1 		$0 Buy
+6
New +$208 ﹤0.01% 1943

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berman Capital Advisors's ITCI Position: Q3 2021 in Review

Berman Capital Advisors increased its Intra-Cellular Therapies Inc. (ITCI) stake by 500% in Q3 2021, buying an estimated $1.04K and bringing the position to 36 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Berman Capital Advisors first reported a position in ITCI in Q1 2021 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold ITCI as of Q3 2021.

  • Berman Capital Advisors held 36 shares of Intra-Cellular Therapies Inc. worth $1K as of Q3 2021.
  • Berman Capital Advisors bought 30 Intra-Cellular Therapies Inc. shares in Q3 2021, an estimated $1.04K.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2001 holding.
  • Berman Capital Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2021 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.